FDA, NIH Devise Regulatory Research Agenda, Look For Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Science Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translation Science Awards program.
You may also be interested in...
NIH Translational Science Center Becomes A (Cash-limited) Reality
NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.
NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
NIH Translational Research Consortium Mulls How Best To Leverage Agency's Stake In Industry, Academia, Government Relationships
"We all have different carrots and different challenges, but we also have a great deal in common, including the goal to provide improved treatments and preventions for the public," says NCRR Director Alving.